Table 2 ICI monotherapy for advanced HCC
From: Recent advances in systemic therapy for hepatocellular carcinoma
ICI | Setting | Target | Phase | Name/NCT No. | Results | Approval Status |
|---|---|---|---|---|---|---|
Tremelimumab | 1st/2nd | CTLA-4 | II | NCT01008358 | / | / |
Durvalumab | 1st/2nd | PD-L1 | I/II | NCT01693562 | / | / |
2nd | III | NCT03847428 | / | / | ||
Avelumab | 2nd | PD-L1 | II | NCT03389126 | ORR 10%, DCR 73.3%, mTTP 4.4 months, mOS 14.2 months | / |
Nivolumab | 2nd | PD-1 | I/II | CheckMate-040 | ORR 20%, mPFS 4.0 months | Conditional second-line, 2017 |
1st | III | CheckMate-459 | ORR 15%, mPFS 16.4 months | / | ||
Pembrolizumab | 1st/2nd | PD-1 | II | KEYNOTE-224 | ORR 17%, mOS 12.9 months, mPFS 4.9 months, mTTP 4.9 months | Conditional second-line, 2018 |
1st setting: ORR 16%, DCR 57%, mOS 17 months | / | |||||
2nd | Â | III | KEYNOTE-240 | ORR 18.3%, DCR 61.9%, mOS 13.9 months, mPFS 3.3 months | / | |
2nd | Â | III | KEYNOTE-394 | / | / | |
2nd | Â | III | KEYNOTE-937 | / | / | |
Tislelizumab | 1st | PD-1 | III | RATIONALE-301 | / | / |
Camrelizumab | 2nd | PD-1 | II | NCT02989922 | ORR 14.7%, 6-month OS 74.4% | / |